Application of D-mannose in preparation of product for improving immunity of pet cat and / or regulating intestinal health of pet cat

Abstract

The invention provides application of D-mannose in preparation of a product for improving immunity of a pet cat and / or regulating intestinal health of the pet cat, and belongs to the technical field of pet nutrition regulation and control. It is found that D-mannose can significantly improve the content of serum immune globulin IgG of pet cats and enhance the immunity of the pet cats; in the aspect of regulating the intestinal health, the D-mannose can improve the flora health index of ASV level and genus level in the intestinal flora of the pet cat, reduce the flora imbalance index, increase the abundance of intestinal fecal coccus, reduce the abundance of peptobacter spp. And milk microbe, and maintain the microecological balance of the intestinal tract. The invention has the advantages of wide applicable groups, abundant product forms, high safety and good tolerance, and can be added into pet food for a long time. The pet cat feed can effectively improve the immunity and intestinal flora homeostasis of pet cats, improves the health condition of the pet cats, and provides a new solution for nutrition and health of the pet cats.

Description

Technical Field

[0001] The present invention belongs to the technical field of pet nutrition regulation, and in particular relates to the use of D-mannose in the preparation of products for improving the immunity of pet cats and / or regulating the intestinal health of pet cats. Background Art

[0002] With socioeconomic development and changes in people's lifestyles, the status of companion animals in human society continues to rise, and their health issues are receiving increasing attention. Simultaneously, pet food research and development has shifted toward nutritionally balanced and health-promoting products. Cats, as a key companion animal, often suffer from decreased immunity and intestinal dysfunction due to factors such as genetics, stress, diet, and infection. Their immune function and intestinal health are of particular interest for research. Epidemiological surveys show that the most common diseases in pet cats today include dermatophytosis, upper respiratory tract infections, inflammatory bowel disease (IBD), and feline infectious peritonitis (FIP). The vast majority of these diseases are related to weakened immunity and environmental infections, ranging from mild to life-threatening. Feline IBD can also be accompanied by inflammation of other organs, such as pancreatitis and cholangitis, leading to severe multi-organ disease. Immunity is crucial for disease prevention and treatment. Studies have shown that improving immunity may help treat tumors and infections from various pathogens by enhancing autophagy. Notably, there is a complex interplay between immune function and intestinal health. Imbalanced immune regulation can lead to impaired intestinal barrier function, prompting the translocation of intestinal flora and their metabolites into the bloodstream, which in turn triggers systemic low-grade inflammation and abnormal immune activation. Maintaining intestinal homeostasis promotes better digestion and absorption of nutrients, enhances immune balance, and prevents hyperimmunity and chronic inflammation.

[0003] Currently, drug intervention and nutritional regulation are important means to improve pet immunity and intestinal health. Unlike drug intervention, nutritional regulation is easy to implement, less likely to produce side effects, and suitable for long-term use. It has unique advantages in immune regulation and disease prevention. At present, research mainly focuses on polyunsaturated fatty acids, plant extracts, probiotics and prebiotics, but these drug alternatives have potential defects, among which safety, stability and bioavailability are the main problems. First, the safety assessment system of existing functional additives is still imperfect. Although many plant extracts have shown immunomodulatory potential in in vitro experiments or short-term feeding, their long-term safety data are scarce, which may lead to cumulative liver and kidney damage or allergic reactions. Secondly, the stability of additives is a prominent issue. Probiotics have a low survival rate in the high temperature and high pressure environment during pet food processing and are easily inactivated when stored at room temperature. In addition, the low pH value of cat gastric acid may destroy the activity of microecological preparations, resulting in insufficient effective dose actually reaching the intestine. Third, bioavailability is limited. Polyunsaturated fatty acids (such as EPA / DHA) are easily oxidized and deteriorate, while fat-soluble plant active ingredients (such as curcumin) have extremely low absorption rates in the feline intestine. This requires synergistic technologies such as nanoemulsification, but these processes are costly and difficult to commercialize. These issues hinder the widespread application of these functional nutritional additives. Summary of the Invention

[0004] In view of this, the purpose of the present invention is to provide the use of D-mannose in the preparation of products for improving the immunity of pet cats and / or regulating the intestinal health of pet cats. D-mannose has a positive effect on improving the immunity and intestinal health of pet cats, which is manifested in two aspects: increasing the level of plasma immunoglobulin IgG and improving the composition of the flora, thereby helping to alleviate the immune disorders and intestinal flora disorders of pet cats caused by various factors.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides the use of D-mannose in preparing a product for improving the immunity of a pet cat and / or regulating the intestinal health of a pet cat.

[0007] Preferably, the step of improving the immunity of the pet cat comprises increasing the level of immunoglobulin IgG in the serum of the pet cat.

[0008] Preferably, the regulating the intestinal health of the pet cat includes increasing the ASV level and the flora health index at the genus level in the intestinal flora of the pet cat, and reducing the flora imbalance index.

[0009] More preferably, the regulating the intestinal health of the pet cat includes increasing the abundance of Coprococcus in the intestinal tract of the pet cat and reducing the abundance of Peptibacillus flatus and Milk Microbacterium Marseille.

[0010] Preferably, the pet cats include kittens, adult cats, elderly cats and cats with immunodeficiency or chronic intestinal diseases.

[0011] The present invention also provides a product for improving the immunity of a pet cat and / or regulating the intestinal health of a pet cat, wherein the product is added with D-mannose.

[0012] Preferably, the products include feed additives, feed, functional snacks, sustained-release preparations and compound preparations.

[0013] More preferably, the feed includes dry food, wet food and freeze-dried food, and the content of D-mannose is 1-2 wt%.

[0014] More preferably, the functional snacks include cat strips, meat paste and chewable tablets, and the content of D-mannose is 5-20 wt%.

[0015] More preferably, the content of D-mannose in the sustained-release preparation and the compound preparation is 50-80 wt %.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The present invention found that D-mannose is effective in improving the immunity of pet cats and regulating intestinal health. Among them, supplementation of D-mannose can significantly increase the content of immunoglobulin IgG in the serum of pet cats. IgG plays a key role in immune defense. It can neutralize pathogens, enhance phagocyte function, activate the complement system, and mediate cytotoxicity. The increase in its content effectively enhances the anti-infection ability of pet cats and reduces the chance of illness. D-mannose can also improve the health index of the intestinal flora of pet cats at the ASV level and genus level, while reducing the dysbacteriosis index and maintaining the stability of the intestinal microecology. At the species level, D-mannose increases the number of Coccoccus, which participates in the synthesis of short-chain fatty acids, helps to strengthen the intestinal barrier function and improve metabolism; it also reduces the abundance of Bacillus cirrhosae, reduces the production of deoxycholic acid, and reduces the risk of enteritis.

[0018] Furthermore, the present invention has wide applicable groups, rich applicable product forms, high safety, good tolerance, and can be added to pet food for a long time. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Effects of D-mannose supplementation on serum immunoglobulin levels in adult cats; in the figure, * indicates significant difference compared with the control group (P < 0.05), n = 9.

[0020] Figure 2Effects of D-mannose supplementation on the intestinal flora health index and imbalance index of adult cats; in the figure, * indicates a significant difference compared with the control group, P < 0.05; ** indicates a very significant difference compared with the control group, P < 0.01; *** indicates an extremely significant difference compared with the control group, P < 0.001, n = 9.

[0021] Figure 3 Species-level differential bacterial community analysis; in the figure, A is a multi-level species difference LDA discriminant diagram, based on abundance normalization comparison (All-against-all method), bacterial taxa with LDA values greater than 2 were selected as biomarker groups; B, C, and D are Wilcoxon rank sum test analysis at the species level of intestinal flora, corrected by FDR multiple test, and analysis showing the inter-group differences of major bacterial communities at the species level, bootstrap = 0.95, n = 9; * indicates significant difference compared with the control group, P < 0.05. DETAILED DESCRIPTION

[0022] The present invention provides the use of D-mannose in preparing a product for improving the immunity of a pet cat and / or regulating the intestinal health of a pet cat.

[0023] In the present invention, improving the immunity of a pet cat preferably includes increasing the level of immunoglobulin IgG in the pet cat's serum. IgG maintains the immunity of a pet cat through multiple mechanisms, including neutralizing pathogens, enhancing phagocytosis, activating complement, and mediating cytotoxicity. Its level and function directly affect the pet cat's ability to resist infection.

[0024] In the present invention, preferably, regulating the intestinal health of pet cats includes increasing the ASV level and the flora health index at the genus level in the intestinal flora of pet cats, and reducing the flora imbalance index; further preferably, it includes increasing the abundance of Coprococcus in the intestinal tract of pet cats, and reducing the abundance of Bacillus bisporus and Bacillus marseilles. Coprococcus is involved in the synthesis of short-chain fatty acids, which can enhance the intestinal barrier function and improve the metabolic health of pet cats; Bacillus bisporus can convert taurocholic acid into deoxycholic acid, and the increase in deoxycholic acid levels can lead to the aggravation of enteritis by activating inflammasomes, increasing the level of pro-inflammatory factors, or promoting ferroptosis. The inhibitory effect of D-mannose on the abundance of Bacillus bisporus helps to maintain the health of the intestine to a certain extent and reduce the risk of enteritis in pet cats.

[0025] In the present invention, preferred pet cats include kittens (from weaning to 12 months old), adult cats (2-6 years old), elderly cats (over 7 years old), and cats with immunodeficiency or chronic intestinal diseases, such as cats with IBD. The present invention is applicable to a wide range of groups.

[0026] The present invention also provides a product for improving the immunity and / or regulating the intestinal health of pet cats, wherein the product is supplemented with D-mannose. The present invention does not particularly limit the source of the D-mannose, including but not limited to industrial synthesis, microbial fermentation, and plant-derived D-mannose.

[0027] In the present invention, preferred products include feed additives, feed, functional snacks, sustained-release preparations and compound preparations.

[0028] In the present invention, it is further preferred that D-mannose is directly used as a feed additive and added to the feed, and more preferably the addition amount is 1-2 wt%.

[0029] In the present invention, it is further preferred that the feed includes dry food, wet food and freeze-dried food, and the content of D-mannose is 1-2 wt %, which is adjusted according to body weight and health status, and is more preferably 1.5 wt %.

[0030] In the present invention, it is further preferred that the functional snacks include cat strips, meat paste and chewable tablets, and the content of D-mannose is 5-20wt%, which is adjusted according to body weight and health status, and is more preferably 10wt%.

[0031] In the present invention, the D-mannose content in the sustained-release formulation and the compound formulation is further preferably 50-80 wt %, with the content adjusted based on body weight and health status, and more preferably 65 wt %. In one embodiment, the sustained-release formulation is microencapsulated D-mannose; the compound formulation is a combination of D-mannose with probiotics, prebiotics, postbiotics, short-chain fatty acids, and the like.

[0032] The technical solutions provided by the present invention are described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0033] Example 1

[0034] A dry food for improving the immunity and intestinal health of pet cats, the ingredients are as follows:

[0035] Freeze-dried chicken 45wt%, pea protein powder 18wt%, tapioca starch 15wt%, coconut powder 8wt%, chicken fat 7wt%, premix (vitamins, minerals) 3wt%, D-mannose 1.5wt%, brewer's yeast powder 1.2wt%, choline chloride 0.5wt%, rosemary extract 0.3wt%, adhesive 0.5wt%.

[0036] Example 2

[0037] A cat strip for improving the immunity and intestinal health of a pet cat, comprising the following ingredients:

[0038] Salmon surimi 50wt%, hydrolyzed collagen 10wt%, D-mannose 10wt%, oligofructose 5wt%, animal Bifidobacterium 2wt%, guar gum 1wt%, potassium sorbate 0.1wt%, and the balance is purified water.

[0039] Example 3

[0040] A sustained-release preparation for improving the immunity and intestinal health of pet cats is added with 60 wt% D-mannose; the D-mannose and zinc oxide are microencapsulated by fluidized bed coating technology (the coating material is ethyl cellulose).

[0041] Test example

[0042] Animal testing

[0043] Eighteen adult British Shorthair cats (8 males, weighing 4.74 ± 0.17 kg; 10 females, weighing 3.11 ± 0.10 kg) were enrolled in the study. Cats were randomly divided into two groups (9 each, 4 males and 5 females, housed individually) based on body weight. The two treatment groups were supplemented with 0.5 g / kg / day of D-glucose (control group) and 0.5 g / kg / day of D-mannose (treatment group). D-glucose / D-mannose powder was mixed into cat strips at a 20% (w / w) concentration and administered orally. The formal trial lasted 14 days, with all cats receiving free access to food and water. The remaining feed was weighed at 9:00 AM daily, and the average feed intake was calculated. Each cat was weighed on days 0, 7, and 14, and the average daily weight gain was calculated. Fecal scores and diarrhea were recorded daily during fecal cleaning. Fresh feces and blood were collected from each cat on day 14. The experimental diet was a commercial diet (Royal Pet Food Co., Ltd., France) that met the NRC (2006) feed formulation standards. The nutritional composition is shown in Table 1 (dry matter basis):

[0044] Table 1 Nutrient composition of experimental diets

[0045] Element content Crude protein, % 32.20 Total fat, % 14.10 Crude ash, % 7.10 calcium,% 1.11 Total phosphorus, % 1.00 Moisture,% 6.00 Total energy, MJ / kg 20.22

[0046] Husbandry and Management: This trial was conducted at a pet nutrition research center in Beijing. Routine disinfection was performed before the trial officially began. Husbandry and management conditions were maintained uniformly across all groups throughout the trial period. The cattery temperature was 20-25°C, the humidity was 50%-60%, and the cattery was well ventilated. Husbandry and cleaning procedures were followed according to standard cattery management procedures. The trial was conducted in strict accordance with the requirements of the Animal Ethics Committee of China Agricultural University (Animal Ethics Committee Approval Number: AW70114202-1-09).

[0047] Slaughter and Sample Collection: On day 14 of the study, fresh fecal samples were collected from each cat, quickly frozen in dry ice, and stored at -80°C until analysis. On day 14 of the study, blood was collected from the lateral saphenous vein of the hind limb of all cats while fasting. Prior to blood collection, the cats were ensured to be in a stable position. The saphenous vein was located on the skin of the lateral lower third of the tibia. After identifying the blood collection site, the hair was clipped and the skin was disinfected with medical alcohol. A tourniquet was placed above the clipped area to allow the underlying vein to swell. Blood was then rapidly drawn from the vein using a syringe with a needle. Part of the blood sample was placed in an anticoagulant tube containing EDTA-2K for routine blood tests. The remaining blood sample was refrigerated at 4°C for 1 hour to allow for coagulation and stratification. After centrifugation at 4000 rpm for 10 minutes, the upper serum layer was transferred to a fresh centrifuge tube for determination of blood biochemical parameters.

[0048] Routine blood count: The following parameters were measured by an automatic hematology analyzer: white blood cell count (WBC), neutrophil count (Neu), lymphocyte count (Lym), monocyte count (Mon), eosinophil count (Eos), basophil count (Bas), neutrophil percentage (Neu%), lymphocyte percentage (Lym%), monocyte percentage (Mon%), eosinophil percentage (Eos%), basophil percentage (Bas%), red blood cell count (RBC), hemoglobin concentration (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin content (MCH), mean corpuscular hemoglobin concentration (MCH), coefficient of variation of red blood cell distribution width (RDW-CV), standard deviation of red blood cell distribution width (RDW-SD), platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and platelet count (PCT).

[0049] Serum biochemical analysis: The following indicators were measured using an automatic biochemical analyzer: total protein (TP), glucose (GLU), blood urea nitrogen (BUN), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and creatinine (CRE).

[0050] Determination of serum antioxidant indexes and serum immunoglobulin content: Serum superoxide dismutase (SOD), reduced glutathione (GSH) and malondialdehyde (MDA) were determined using Solebol kits, and serum IgA, IgG and IgM were determined by colorimetry by Beijing Huaying Biotechnology Research Institute. The specific detection steps were carried out strictly in accordance with the kit instructions and instrument instructions, and the results were analyzed after calculation according to the formula.

[0051] Intestinal flora DNA extraction and 16S rRNA sequencing analysis: After the end of the trial period, fresh feces were collected, quickly frozen in dry ice, and transferred to a -80℃ refrigerator for storage, and then intestinal flora analysis was performed.

[0052] (1) DNA extraction: Total genomic DNA was extracted from cat fecal microbial communities using the PF Mag-Bind Stool DNA Kit (Omega Bio-tek, Norcross, GA, USA). DNA quality was verified by electrophoresis on a 1% agarose gel. DNA concentration and purity were determined using a NanoDrop 2000 instrument.

[0053] (2) PCR amplification and construction of sequencing library: Using the extracted DNA as a template, the specific upstream primer 27F (5'-AGRGTTYGATYMTGGCTCAG-3', as shown in SEQ ID NO.1) and downstream primer 1492R (5'-RGYTACCTTGTTACGACTT-3', as shown in SEQ ID NO.2), which carry unique barcode sequences, were used to PCR amplify the V3-V4 variable region of the 16S rRNA gene. The specific PCR reaction system is as follows: 4 μL of 5×FastPfu buffer, 2 μL of 2.5 mM dNTPs, 0.8 μL of upstream and downstream primers (concentration of 5 μM), 0.4 μL of FastPfu DNA polymerase, and 10 ng of template DNA, and the total volume was made up to 20 μL. ABI PCR amplification was performed using a 9700 PCR instrument with the following program settings: 95°C pre-denaturation for 3 min, followed by 27 cycles (each cycle included 95°C denaturation for 30 s, 55°C annealing for 30 s, and 72°C extension for 30 s), and finally 72°C extension for 10 min. PCR products were recovered and purified using 2% agarose gel. The recovered products were again subjected to 2% agarose gel electrophoresis to detect their band fragment size, and the Quantus TM Fluorometer (Promega, USA) was used for quantitative detection.

[0054] High-throughput sequencing data analysis: Purified PCR products were sequenced (2 × 300 bp) using the Pacbio Sequel IIe System. Sequencing data were processed using the analysis pipeline provided by Meiji Biotechnology, including removal of low-quality sequences, splicing of paired-end sequences, removal of chimeras, and ASV noise reduction. ASV species taxonomy was annotated using the RDP classifier (version 2.13) against the Silva 16S rRNA gene database (v138). Alpha-diversity (e.g., Shannon index, Sob index) and beta-diversity (e.g., PCA analysis) were also performed. Nonparametric tests were used to analyze whether microbial community structure differed significantly between sample groups. Lexical element-sequencing (LEfSe) was used to identify bacterial taxa with significant differences in abundance between groups at the phylum and genus levels, and differences were analyzed using the Wilcoxon rank sum test. All data analyses were performed using the online analysis platform provided by Meiji Biotechnology.

[0055] Test results:

[0056] (1) Adult cats were orally administered D-glucose or D-mannose for 14 consecutive days. After the end of the experimental period, blood samples from the anterior vena cava and fresh fecal samples were collected. Food intake, diarrhea rate (no diarrhea occurred), and fecal scores were recorded throughout the experimental period. Blood parameters and changes in intestinal flora were evaluated. After analysis, the following conclusions were drawn: Compared with the control group, supplementation with 5g / kg D-mannose significantly enhanced immunity and intestinal flora homeostasis without affecting food intake, growth performance, and fecal scores.

[0057] (2) Routine blood tests: As shown in Table 2, supplementation with 0.5 g / kg D-mannose changed some of the routine blood tests in adult cats. Among the red blood cell-related indices, the hemoglobin concentration (HGB), mean corpuscular volume (MCV), mean corpuscular hemoglobin content (MCH), and standard deviation of red blood cell distribution width (RDW-SD) in the D-mannose group were significantly increased (P < 0.05); there were no significant differences in red blood cell count (RBC), hematocrit (HCT), mean corpuscular hemoglobin concentration (MCHC), and coefficient of variation of red blood cell distribution width (RDW-CV) (P > 0.05). Among the platelet-related indices, the mean platelet volume (MPV), platelet distribution width (PDW), and platelet hemoglobin (PCT) in the D-mannose group were significantly higher than those in the control group (P < 0.05); there was no significant difference in platelet count (PLT) in the D-mannose group compared with the control group (P > 0.05). Among immune cell-related indicators, no significant differences were observed between the two groups for white blood cell count (WBC), neutrophil count (Neu), lymphocyte count (Lym), monocyte count (Mon), eosinophil count (Eos), and basophil count (Bas) (P>0.05). Furthermore, no significant differences were observed in the D-mannose group for neutrophil percentage (Neu%), lymphocyte percentage (Lym%), monocyte percentage (Mon%), eosinophil percentage (Eos%), and basophil percentage (Bas%) (P>0.05), suggesting that D-mannose has no effect on the proportions of immune cell subsets. In summary, D-mannose can increase HGB, MCV, MCH, and RDW-SD in adult cats within the physiological range, and these changes are beneficial for improving the functional status of red blood cells and platelets.

[0058] Table 2 Effects of D-mannose supplementation on blood routine in adult cats

[0059]

[0060]

[0061] (3) Blood biochemical indices: As shown in Table 3, supplementation of 0.5 g / kg D-mannose had no significant effect on the blood biochemical indices of adult cats.

[0062] Table 3 Effects of D-mannose supplementation on plasma biochemical parameters in adult cats

[0063] project Control group (D-glucose) Treatment group (D-mannose) P-value TP, g / L 74.13±2.97 75.42±2.53 0.75 GLU, mmol / L 5.64±0.29 5.49±0.26 0.70 BUN, mmol / L 5.58±0.32 5.65±0.33 0.87 ALT, U / L 83.11±11.40 62.38±10.28 0.20 ALP, U / L 30.22±4.29 26.22±2.65 0.44 CRE, μmol / L 84.11±5.95 93.44±4.66 0.23

[0064] (4) Serum antioxidant indexes and serum immunoglobulin content: As shown in Table 4, supplementation of 0.5 g / kg D-mannose had no significant effect on the levels of superoxide dismutase (SOD), reduced glutathione (GSH) and malondialdehyde (MDA) in the serum of adult cats. Figure 1 As shown, supplementation of 0.5 g / kg D-mannose significantly increased the content of serum immunoglobulin IgG in adult cats, indicating that supplementation of D-mannose can improve the immunity of adult cats.

[0065] Table 4 Effects of D-mannose supplementation on serum antioxidant indices in adult cats

[0066] project Control group (D-glucose) Treatment group (D-mannose) P-value SOD, U / mL 14.08±0.59 15.47±1.05 0.12 GSH, μg / mL 6.89±0.88 5.28±0.11 0.35 MDA, nmol / mL 8.11±0.46 7.00±0.59 0.16

[0067] (5) 16S rRNA sequencing: Sequencing results showed that Figure 2-3 As shown, the ASV level and genus-level microbial health index in the intestinal microbiota of adult cats supplemented with D-mannose were significantly increased compared with the control group (P<0.001, P<0.01), while the microbial dysbiosis index in the D-mannose group was significantly lower than that in the control group at both the ASV level and the genus level (P<0.001, P<0.01), indicating that D-mannose helps improve intestinal microbiota homeostasis. Notably, D-mannose significantly increased the abundance of Coprococcus sp. AF21-14LB (involved in the synthesis of short-chain fatty acids, which can enhance intestinal barrier function and improve host metabolic health), while significantly reducing the abundance of Peptacetobacter hiranonis (associated with secondary bile acid synthesis) and Lactimicrobium massiliense (specific function unknown). Peptacetobacter hiranonis can convert taurocholic acid into deoxycholic acid. Increased levels of deoxycholic acid can exacerbate enteritis by activating inflammasomes, increasing levels of pro-inflammatory cytokines, or promoting ferroptosis. Therefore, D-mannose's inhibitory effect on the abundance of Peptacetobacter hiranonis may help maintain intestinal health and reduce the risk of enteritis in adult cats.

[0068] Based on the above results, supplementation with D-mannose can improve the immunity and intestinal flora homeostasis of adult cats and improve their health. The present invention has high safety, good tolerance, and has a good effect on improving the immunity and intestinal health of adult cats.

[0069] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. Application of D-mannose in the preparation of products for improving the immunity of pet cats and / or regulating the intestinal health of pet cats.

2. The use according to claim 1, characterized in that The method of improving the immunity of the pet cat includes improving the content of immunoglobulin IgG in the serum of the pet cat.

3. The use according to claim 1, characterized in that The regulating of the intestinal health of the pet cat includes increasing the ASV level and the flora health index at the genus level in the intestinal flora of the pet cat, and reducing the flora imbalance index.

4. The use according to claim 1 or 3, characterized in that The method of regulating the intestinal health of pet cats includes increasing the abundance of Coccus in the intestinal tract of pet cats and reducing the abundance of Peptibacterium flatulum and Bacillus Marseille.

5. The use according to claim 1, characterized in that The pet cats include kittens, adult cats, elderly cats and cats with immunodeficiency or chronic intestinal diseases.

6. A product for improving the immunity of pet cats and / or regulating the intestinal health of pet cats, characterized in that: The product is supplemented with D-mannose.

7. The product according to claim 6, characterized in that The products include feed additives, feed, functional snacks, sustained-release preparations and compound preparations.

8. The product according to claim 7, characterized in that The feed includes dry food, wet food and freeze-dried food, and the content of D-mannose is 1-2wt%.

9. The product according to claim 7, characterized in that The functional snacks include cat strips, meat paste and chewable tablets, and the content of D-mannose is 5-20 wt%.

10. The product according to claim 7, characterized in that The content of D-mannose in the sustained-release preparation and the compound preparation is 50-80 wt %.

Images